BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

811 related articles for article (PubMed ID: 14729633)

  • 1. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
    Whittaker SR; Walton MI; Garrett MD; Workman P
    Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of the actin cytoskeleton leads to inhibition of mitogen-induced cyclin E expression, Cdk2 phosphorylation, and nuclear accumulation of the retinoblastoma protein-related p107 protein.
    Reshetnikova G; Barkan R; Popov B; Nikolsky N; Chang LS
    Exp Cell Res; 2000 Aug; 259(1):35-53. PubMed ID: 10942577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
    Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F
    Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells.
    Yin F; Giuliano AE; Law RE; Van Herle AJ
    Anticancer Res; 2001; 21(1A):413-20. PubMed ID: 11299771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells.
    Shukla S; Gupta S
    Cell Cycle; 2007 May; 6(9):1102-14. PubMed ID: 17457054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) on the physiology of cultured human keratinocytes.
    Atanasova G; Jans R; Zhelev N; Mitev V; Poumay Y
    Biochem Pharmacol; 2005 Sep; 70(6):824-36. PubMed ID: 16011834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1).
    Cheng M; Sexl V; Sherr CJ; Roussel MF
    Proc Natl Acad Sci U S A; 1998 Feb; 95(3):1091-6. PubMed ID: 9448290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
    Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
    Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential responses of skin cancer-chemopreventive agents silibinin, quercetin, and epigallocatechin 3-gallate on mitogenic signaling and cell cycle regulators in human epidermoid carcinoma A431 cells.
    Bhatia N; Agarwal C; Agarwal R
    Nutr Cancer; 2001; 39(2):292-9. PubMed ID: 11759294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CaMK-II inhibition reduces cyclin D1 levels and enhances the association of p27kip1 with Cdk2 to cause G1 arrest in NIH 3T3 cells.
    Morris TA; DeLorenzo RJ; Tombes RM
    Exp Cell Res; 1998 May; 240(2):218-27. PubMed ID: 9596994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of p38 mitogen-activated protein kinase in the cell growth inhibition by sodium arsenite.
    Kim JY; Choi JA; Kim TH; Yoo YD; Kim JI; Lee YJ; Yoo SY; Cho CK; Lee YS; Lee SJ
    J Cell Physiol; 2002 Jan; 190(1):29-37. PubMed ID: 11807808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells.
    Fiddes RJ; Janes PW; Sivertsen SP; Sutherland RL; Musgrove EA; Daly RJ
    Oncogene; 1998 May; 16(21):2803-13. PubMed ID: 9652748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest.
    Datta NS; Chen C; Berry JE; McCauley LK
    J Bone Miner Res; 2005 Jun; 20(6):1051-64. PubMed ID: 15883646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
    Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.
    Lavoie JN; L'Allemain G; Brunet A; Müller R; Pouysségur J
    J Biol Chem; 1996 Aug; 271(34):20608-16. PubMed ID: 8702807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
    Watts CK; Brady A; Sarcevic B; deFazio A; Musgrove EA; Sutherland RL
    Mol Endocrinol; 1995 Dec; 9(12):1804-13. PubMed ID: 8614416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogens do not modify MAP kinase-dependent nuclear signaling during stimulation of early G(1) progression in human breast cancer cells.
    Caristi S; Galera JL; Matarese F; Imai M; Caporali S; Cancemi M; Altucci L; Cicatiello L; Teti D; Bresciani F; Weisz A
    Cancer Res; 2001 Sep; 61(17):6360-6. PubMed ID: 11522626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
    Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
    Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells.
    Kortylewski M; Heinrich PC; Kauffmann ME; Böhm M; MacKiewicz A; Behrmann I
    Biochem J; 2001 Jul; 357(Pt 1):297-303. PubMed ID: 11415463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.